ClinicalTrials.gg

Program

inpegsomatropin

Also written as “Inpegsomatropin Injection” and “Inpegsomatropin-Injection”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome, led by Xiamen Amoytop Biotech.

Furthest: phase 3, since Apr 6, 20255 company-led studies, 5 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xiamen Amoytop Biotech55 open or runningphase 3since Apr 6, 2025Apr 6, 2025Dec 31, 2027phase 2 · NCT07551804

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2025First study: phase 3 study in Idiopathic Short StatureFirst studyNCT06927310 · 300 planned · China
  2. Dec 15, 2025Phase 3 study in Small for Gestational AgeNCT07309562 · 141 planned · China
  3. Apr 15, 2026Phase 2 study in Dwarfism, PituitaryNCT07551804 · 36 planned · China
  4. May 21, 2026Phase 3 study in Turner SyndromeNCT07614152 · 84 planned · China
  5. Oct 9, 2026No phase study in Idiopathic Short StatureNCT07894341 · 300 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Dwarfism, PituitaryNCT07551804
  2. Mar 2028Primary completion: phase 3 study in Small for Gestational AgeNCT07309562
  3. Mar 30, 2028Primary completion: phase 3 study in Turner SyndromeNCT07614152
  4. Aug 31, 2041Primary completion: no phase study in Idiopathic Short StatureNCT07894341

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07894341Idiopathic Short Stature · China–RecruitingAug 31, 2041300
NCT07614152Turner Syndrome · China3RecruitingMar 30, 202884
NCT07551804Dwarfism, Pituitary · China2RecruitingDec 31, 202736
NCT07309562Small for Gestational Age · China3RecruitingMar 2028141
NCT06927310Idiopathic Short Stature · China3RecruitingMar 2026300

How it is read

Names in the registry

  • “Inpegsomatropin Injection”, 7 entries
  • “Inpegsomatropin-Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.